United States Biotechnology & Medical Research

Arrowhead Pharmaceuticals Inc (ARWR)

Track

In the last 90 days, Arrowhead Pharmaceuticals Inc. has seen significant insider selling, with total sales exceeding $5.7 million. Notably, officers and executives like Daniel Apel and James Hamilton have engaged in multiple planned and proposed sales. There have been no insider purchases recorded during this period. The stock has performed strongly, with a 90-day price change of 43.9%.

Not featured in screeners

Featured in screeners

Not featured in screeners

Stock chart

Ticker: ARWR Exchange: NSM

Subscribe to get access to the transaction volume chart and in-chart transaction details

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Hongbo Lu

Officer

2 sales — total 456,598 USD

Proposed sale 12 May 2026

Value US$2,061,506.05 | Price 181.85 | Shares 89,546

Proposed sale 12 May 2026

Value US$770,172.42 | Price 322.81 | Shares 21,319

Lu Hongbo

1 sale — total 228,334 USD

Planned sale 12 May 2026

Value US$1,855,106.49 | Price 171.81 | Shares 89,019

James Hamilton

Officer

2 sales — total 1,499,995 USD

Proposed sale 23 Apr 2026

Value US$749,997.60 | Price 75.00 | Shares 10,000

Proposed sale 23 Apr 2026

Value US$749,997.60 | Price 75.00 | Shares 10,000

Hamilton James C

Chief Medical Officer

1 sale — total 750,000 USD

Planned sale 23 Apr 2026

Value US$750,000.00 | Price 75.00 | Shares 10,000

Daniel Apel

Officer

2 sales — total 1,868,412 USD

Proposed sale 22 Apr 2026

Value US$934,206.16 | Price 71.34 | Shares 13,095

Proposed sale 22 Apr 2026

Value US$934,206.16 | Price 71.34 | Shares 13,095

Apel Daniel Joseph

Chief Financial Officer

3 sales — total 934,285 USD

Planned sale 22 Apr 2026

Value US$627,861.60 | Price 71.92 | Shares 8,730

Planned sale 22 Apr 2026

Value US$81,510.65 | Price 70.45 | Shares 1,157

Planned sale 22 Apr 2026

Value US$224,912.88 | Price 70.11 | Shares 3,208

Hamilton James C

Chief Medical Officer

1 sale — total 641,900 USD

Planned sale 5 Mar 2026

Value US$641,900.00 | Price 64.19 | Shares 10,000

James Hamilton

Officer

1 sale — total 641,870 USD

Proposed sale 5 Mar 2026

Value US$641,870.05 | Price 64.19 | Shares 10,000

James Hamilton

Officer

2 sales — total 5,041,105 USD

Proposed sale 5 Jan 2026

Value US$2,534,478.03 | Price 63.10 | Shares 40,164

Proposed sale 5 Jan 2026

Value US$2,506,627.22 | Price 63.09 | Shares 39,728

Patrick O'Brien

Officer

1 sale — total 3,123,172 USD

Proposed sale 5 Jan 2026

Value US$3,123,171.63 | Price 63.10 | Shares 49,493

O'Brien Patrick

COO

12 sales — total 3,123,349 USD

Planned sale 5 Jan 2026

Value US$3,128.00 | Price 68.00 | Shares 46

Planned sale 5 Jan 2026

Value US$149,597.44 | Price 64.04 | Shares 2,336

Planned sale 5 Jan 2026

Value US$369,470.43 | Price 62.91 | Shares 5,873

Planned sale 5 Jan 2026

Value US$56,025.00 | Price 62.25 | Shares 900

Planned sale 5 Jan 2026

Value US$36,672.00 | Price 61.12 | Shares 600

Planned sale 5 Jan 2026

Value US$21,284.00 | Price 68.00 | Shares 313

Planned sale 5 Jan 2026

Value US$59,409.00 | Price 66.01 | Shares 900

Planned sale 5 Jan 2026

Value US$173,988.00 | Price 64.44 | Shares 2,700

Planned sale 5 Jan 2026

Value US$755,993.28 | Price 63.84 | Shares 11,842

Planned sale 5 Jan 2026

Value US$846,874.96 | Price 62.96 | Shares 13,451

Planned sale 5 Jan 2026

Value US$383,585.72 | Price 62.23 | Shares 6,164

Planned sale 5 Jan 2026

Value US$267,321.60 | Price 61.20 | Shares 4,368

Hamilton James C

Chief Medical Officer

7 sales — total 2,534,661 USD

Planned sale 5 Jan 2026

Value US$21,012.00 | Price 68.00 | Shares 309

Planned sale 5 Jan 2026

Value US$28,828.89 | Price 65.97 | Shares 437

Planned sale 5 Jan 2026

Value US$77,388.00 | Price 64.49 | Shares 1,200

Planned sale 5 Jan 2026

Value US$812,868.45 | Price 63.95 | Shares 12,711

Planned sale 5 Jan 2026

Value US$932,043.92 | Price 63.01 | Shares 14,792

Planned sale 5 Jan 2026

Value US$379,285.20 | Price 62.28 | Shares 6,090

Planned sale 5 Jan 2026

Value US$283,235.00 | Price 61.24 | Shares 4,625

Anzalone Christopher Richard

Chief Executive Officer

2 sales — total 871,703 USD

Planned sale 2 Jan 2026

Value US$383,136.69 | Price 66.39 | Shares 5,771

Planned sale 2 Jan 2026

Value US$488,566.08 | Price 65.88 | Shares 7,416

Christopher Anzalone

Officer

1 sale — total 871,668 USD

Proposed sale 2 Jan 2026

Value US$871,667.85 | Price 66.10 | Shares 13,187

Anzalone Christopher Richard

Chief Executive Officer

2 sales — total 3,575,575 USD

Planned sale 29 Dec 2025

Value US$1,136,476.05 | Price 68.69 | Shares 16,545

Planned sale 29 Dec 2025

Value US$2,439,098.73 | Price 69.33 | Shares 35,181

Christopher Anzalone

Officer

1 sale — total 3,575,575 USD

Proposed sale 29 Dec 2025

Value US$3,575,575.42 | Price 69.13 | Shares 51,726

Ferrari Mauro

1 sale — total 527,100 USD

Planned sale 26 Dec 2025

Value US$527,100.00 | Price 70.00 | Shares 7,530

Mauro Ferrari

Director

1 sale — total 527,070 USD

Proposed sale 26 Dec 2025

Value US$527,070.05 | Price 70.00 | Shares 7,530

Anzalone Christopher Richard

Chief Executive Officer

2 sales — total 861,340 USD

Planned sale 22 Dec 2025

Value US$177,219.90 | Price 68.85 | Shares 2,574

Planned sale 22 Dec 2025

Value US$684,119.96 | Price 68.33 | Shares 10,012

Christopher Anzalone

Officer

1 sale — total 861,319 USD

Proposed sale 22 Dec 2025

Value US$861,319.30 | Price 68.43 | Shares 12,586

Waddill William D.

3 sales — total 566,038 USD

Planned sale 19 Dec 2025

Value US$34,265.00 | Price 68.53 | Shares 500

Planned sale 19 Dec 2025

Value US$370,722.51 | Price 68.01 | Shares 5,451

Planned sale 19 Dec 2025

Value US$161,050.56 | Price 66.66 | Shares 2,416

Vakiener Victoria

3 sales — total 679,491 USD

Planned sale 19 Dec 2025

Value US$134,044.40 | Price 68.39 | Shares 1,960

Planned sale 19 Dec 2025

Value US$358,949.57 | Price 67.97 | Shares 5,281

Planned sale 19 Dec 2025

Value US$186,497.37 | Price 66.63 | Shares 2,799

OLUKOTUN ADEOYE Y

3 sales — total 676,623 USD

Planned sale 19 Dec 2025

Value US$56,632.96 | Price 68.48 | Shares 827

Planned sale 19 Dec 2025

Value US$413,887.32 | Price 68.04 | Shares 6,083

Planned sale 19 Dec 2025

Value US$206,103.00 | Price 66.70 | Shares 3,090

Anzalone Christopher Richard

Chief Executive Officer

3 sales — total 909,683 USD

Planned sale 19 Dec 2025

Value US$90,325.12 | Price 68.48 | Shares 1,319

Planned sale 19 Dec 2025

Value US$554,077.47 | Price 68.01 | Shares 8,147

Planned sale 19 Dec 2025

Value US$265,279.93 | Price 66.67 | Shares 3,979

Christopher Anzalone

Officer

1 sale — total 909,632 USD

Proposed sale 19 Dec 2025

Value US$909,632.44 | Price 67.66 | Shares 13,445

William Waddill

Director

1 sale — total 566,001 USD

Proposed sale 19 Dec 2025

Value US$566,000.65 | Price 67.65 | Shares 8,367

Adeoye Olukotun

Director

1 sale — total 676,589 USD

Proposed sale 19 Dec 2025

Value US$676,588.82 | Price 67.66 | Shares 10,000

Victoria Vakiener

Director

1 sale — total 679,464 USD

Proposed sale 19 Dec 2025

Value US$679,463.51 | Price 67.68 | Shares 10,040

Anzalone Christopher Richard

Chief Executive Officer

4 sales — total 5,443,462 USD

Sale 17 Dec 2025

Value US$131,340.30 | Price 66.30 | Shares 1,981

Sale 17 Dec 2025

Value US$64,350.46 | Price 65.53 | Shares 982

Sale 17 Dec 2025

Value US$2,306,232.50 | Price 64.51 | Shares 35,750

Sale 17 Dec 2025

Value US$2,941,538.85 | Price 63.55 | Shares 46,287

Christopher Anzalone

Officer

1 sale — total 5,443,253 USD

Proposed sale 17 Dec 2025

Value US$5,443,252.88 | Price 64.04 | Shares 85,000

Christopher Anzalone

Officer

1 sale — total 3,398,142 USD

Proposed sale 16 Dec 2025

Value US$3,398,141.91 | Price 62.58 | Shares 54,298

Anzalone Christopher Richard

Chief Executive Officer

7 sales — total 2,217,451 USD

Sale 16 Dec 2025

Value US$218,609.27 | Price 67.87 | Shares 3,221

Sale 16 Dec 2025

Value US$11,083.82 | Price 66.77 | Shares 166

Sale 16 Dec 2025

Value US$85,501.00 | Price 65.77 | Shares 1,300

Sale 16 Dec 2025

Value US$64,960.00 | Price 64.96 | Shares 1,000

Sale 16 Dec 2025

Value US$428,235.69 | Price 64.29 | Shares 6,661

Sale 16 Dec 2025

Value US$533,479.44 | Price 62.94 | Shares 8,476

Sale 16 Dec 2025

Value US$875,581.40 | Price 62.12 | Shares 14,095

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2026-05-19	2026-05-12	PrS Proposed sale	3.5 Hongbo Lu Officer Officer	89,546 181.85 US$2,061,506	89,546	181.85	US$2,061,506
2026-05-14	2026-05-12	PlS Planned sale	3.5 Lu Hongbo Non-Executive Director	89,019 -3.2% 171.81 US$1,855,106	89,019 -3.2%	171.81	US$1,855,106
2026-05-12	2026-05-12	PrS Proposed sale	3.5 Hongbo Lu Officer Officer	21,319 322.81 US$770,172	21,319	322.81	US$770,172
2026-05-19	2026-04-23	PrS Proposed sale	3.1 James Hamilton Officer Officer	10,000 75.00 US$749,998	10,000	75.00	US$749,998
2026-04-24	2026-04-23	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	10,000 -4.2% 75.00 US$750,000	10,000 -4.2%	75.00	US$750,000
2026-04-23	2026-04-23	PrS Proposed sale	3.1 James Hamilton Officer Officer	10,000 75.00 US$749,998	10,000	75.00	US$749,998
2026-05-19	2026-04-22	PrS Proposed sale	Daniel Apel Officer Officer	13,095 71.34 US$934,206	13,095	71.34	US$934,206
2026-04-24	2026-04-22	PlS Planned sale	Apel Daniel Joseph Chief Financial Officer Officer	8,730 -5.1% 71.92 US$627,862	8,730 -5.1%	71.92	US$627,862
2026-04-24	2026-04-22	PlS Planned sale	Apel Daniel Joseph Chief Financial Officer Officer	1,157 -0.7% 70.45 US$81,511	1,157 -0.7%	70.45	US$81,511
2026-04-24	2026-04-22	PlS Planned sale	Apel Daniel Joseph Chief Financial Officer Officer	3,208 -1.8% 70.11 US$224,913	3,208 -1.8%	70.11	US$224,913
2026-04-22	2026-04-22	PrS Proposed sale	Daniel Apel Officer Officer	13,095 71.34 US$934,206	13,095	71.34	US$934,206
2026-03-09	2026-03-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	10,000 -4.0% 64.19 US$641,900	10,000 -4.0%	64.19	US$641,900
2026-03-05	2026-03-05	PrS Proposed sale	3.1 James Hamilton Officer Officer	10,000 64.19 US$641,870	10,000	64.19	US$641,870
2026-01-05	2026-01-05	PrS Proposed sale	3.1 James Hamilton Officer Officer	40,164 63.10 US$2,534,478	40,164	63.10	US$2,534,478
2026-01-05	2026-01-05	PrS Proposed sale	3.1 James Hamilton Officer Officer	39,728 63.09 US$2,506,627	39,728	63.09	US$2,506,627
2026-01-05	2026-01-05	PrS Proposed sale	3.3 Patrick O'Brien Officer Officer	49,493 63.10 US$3,123,172	49,493	63.10	US$3,123,172
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	46 -0.0% 68.00 US$3,128	46 -0.0%	68.00	US$3,128
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	2,336 -0.5% 64.04 US$149,597	2,336 -0.5%	64.04	US$149,597
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	5,873 -1.2% 62.91 US$369,470	5,873 -1.2%	62.91	US$369,470
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	900 -0.2% 62.25 US$56,025	900 -0.2%	62.25	US$56,025
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	600 -0.1% 61.12 US$36,672	600 -0.1%	61.12	US$36,672
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	313 -0.1% 68.00 US$21,284	313 -0.1%	68.00	US$21,284
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	900 -0.2% 66.01 US$59,409	900 -0.2%	66.01	US$59,409
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	2,700 -0.6% 64.44 US$173,988	2,700 -0.6%	64.44	US$173,988
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	11,842 -2.4% 63.84 US$755,993	11,842 -2.4%	63.84	US$755,993
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	13,451 -2.6% 62.96 US$846,875	13,451 -2.6%	62.96	US$846,875
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	6,164 -1.2% 62.23 US$383,586	6,164 -1.2%	62.23	US$383,586
2026-01-05	2026-01-05	PlS Planned sale	3.3 O'Brien Patrick COO Officer	4,368 -0.8% 61.20 US$267,322	4,368 -0.8%	61.20	US$267,322
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	309 -0.2% 68.00 US$21,012	309 -0.2%	68.00	US$21,012
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	437 -0.3% 65.97 US$28,829	437 -0.3%	65.97	US$28,829
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	1,200 -0.7% 64.49 US$77,388	1,200 -0.7%	64.49	US$77,388
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	12,711 -6.8% 63.95 US$812,868	12,711 -6.8%	63.95	US$812,868
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	14,792 -7.3% 63.01 US$932,044	14,792 -7.3%	63.01	US$932,044
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	6,090 -2.9% 62.28 US$379,285	6,090 -2.9%	62.28	US$379,285
2026-01-05	2026-01-05	PlS Planned sale	3.1 Hamilton James C Chief Medical Officer Officer	4,625 -2.2% 61.24 US$283,235	4,625 -2.2%	61.24	US$283,235
2026-01-05	2026-01-02	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	5,771 -0.2% 66.39 US$383,137	5,771 -0.2%	66.39	US$383,137
2026-01-05	2026-01-02	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	7,416 -0.2% 65.88 US$488,566	7,416 -0.2%	65.88	US$488,566
2026-01-02	2026-01-02	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	13,187 66.10 US$871,668	13,187	66.10	US$871,668
2025-12-30	2025-12-29	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	16,545 -0.4% 68.69 US$1,136,476	16,545 -0.4%	68.69	US$1,136,476
2025-12-30	2025-12-29	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	35,181 -0.9% 69.33 US$2,439,099	35,181 -0.9%	69.33	US$2,439,099
2025-12-29	2025-12-29	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	51,726 69.13 US$3,575,575	51,726	69.13	US$3,575,575
2025-12-30	2025-12-26	PlS Planned sale	1.4 Ferrari Mauro Non-Executive Director	7,530 -9.8% 70.00 US$527,100	7,530 -9.8%	70.00	US$527,100
2025-12-29	2025-12-26	PrS Proposed sale	1.4 Mauro Ferrari Director Non-Executive Director	7,530 70.00 US$527,070	7,530	70.00	US$527,070
2025-12-23	2025-12-22	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	2,574 -0.1% 68.85 US$177,220	2,574 -0.1%	68.85	US$177,220
2025-12-23	2025-12-22	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	10,012 -0.3% 68.33 US$684,120	10,012 -0.3%	68.33	US$684,120
2025-12-22	2025-12-22	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	12,586 68.43 US$861,319	12,586	68.43	US$861,319
2025-12-23	2025-12-19	PlS Planned sale	2.3 Waddill William D. Non-Executive Director	500 -0.9% 68.53 US$34,265	500 -0.9%	68.53	US$34,265
2025-12-23	2025-12-19	PlS Planned sale	2.3 Waddill William D. Non-Executive Director	5,451 -8.7% 68.01 US$370,723	5,451 -8.7%	68.01	US$370,723
2025-12-23	2025-12-19	PlS Planned sale	2.3 Waddill William D. Non-Executive Director	2,416 -3.7% 66.66 US$161,051	2,416 -3.7%	66.66	US$161,051
2025-12-23	2025-12-19	PlS Planned sale	1.5 Vakiener Victoria Non-Executive Director	1,960 -5.2% 68.39 US$134,044	1,960 -5.2%	68.39	US$134,044
2025-12-23	2025-12-19	PlS Planned sale	1.5 Vakiener Victoria Non-Executive Director	5,281 -12.3% 67.97 US$358,950	5,281 -12.3%	67.97	US$358,950
2025-12-23	2025-12-19	PlS Planned sale	1.5 Vakiener Victoria Non-Executive Director	2,799 -6.1% 66.63 US$186,497	2,799 -6.1%	66.63	US$186,497
2025-12-23	2025-12-19	PlS Planned sale	2.6 OLUKOTUN ADEOYE Y Non-Executive Director	827 -2.4% 68.48 US$56,633	827 -2.4%	68.48	US$56,633
2025-12-23	2025-12-19	PlS Planned sale	2.6 OLUKOTUN ADEOYE Y Non-Executive Director	6,083 -15.0% 68.04 US$413,887	6,083 -15.0%	68.04	US$413,887
2025-12-23	2025-12-19	PlS Planned sale	2.6 OLUKOTUN ADEOYE Y Non-Executive Director	3,090 -7.1% 66.70 US$206,103	3,090 -7.1%	66.70	US$206,103
2025-12-23	2025-12-19	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	1,319 -0.0% 68.48 US$90,325	1,319 -0.0%	68.48	US$90,325
2025-12-23	2025-12-19	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	8,147 -0.2% 68.01 US$554,077	8,147 -0.2%	68.01	US$554,077
2025-12-23	2025-12-19	PlS Planned sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	3,979 -0.1% 66.67 US$265,280	3,979 -0.1%	66.67	US$265,280
2025-12-19	2025-12-19	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	13,445 67.66 US$909,632	13,445	67.66	US$909,632
2025-12-19	2025-12-19	PrS Proposed sale	2.3 William Waddill Director Non-Executive Director	8,367 67.65 US$566,001	8,367	67.65	US$566,001
2025-12-19	2025-12-19	PrS Proposed sale	2.6 Adeoye Olukotun Director Non-Executive Director	10,000 67.66 US$676,589	10,000	67.66	US$676,589
2025-12-19	2025-12-19	PrS Proposed sale	1.5 Victoria Vakiener Director Non-Executive Director	10,040 67.68 US$679,464	10,040	67.68	US$679,464
2025-12-19	2025-12-17	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	1,981 -0.1% 66.30 US$131,340	1,981 -0.1%	66.30	US$131,340
2025-12-19	2025-12-17	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	982 -0.0% 65.53 US$64,350	982 -0.0%	65.53	US$64,350
2025-12-19	2025-12-17	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	35,750 -0.9% 64.51 US$2,306,232	35,750 -0.9%	64.51	US$2,306,232
2025-12-19	2025-12-17	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	46,287 -1.2% 63.55 US$2,941,539	46,287 -1.2%	63.55	US$2,941,539
2025-12-17	2025-12-17	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	85,000 64.04 US$5,443,253	85,000	64.04	US$5,443,253
2025-12-16	2025-12-16	PrS Proposed sale	2.7 Christopher Anzalone Officer Officer	54,298 62.58 US$3,398,142	54,298	62.58	US$3,398,142
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	3,221 -0.1% 67.87 US$218,609	3,221 -0.1%	67.87	US$218,609
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	166 -0.0% 66.77 US$11,084	166 -0.0%	66.77	US$11,084
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	1,300 -0.0% 65.77 US$85,501	1,300 -0.0%	65.77	US$85,501
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	1,000 -0.0% 64.96 US$64,960	1,000 -0.0%	64.96	US$64,960
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	6,661 -0.2% 64.29 US$428,236	6,661 -0.2%	64.29	US$428,236
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	8,476 -0.2% 62.94 US$533,479	8,476 -0.2%	62.94	US$533,479
2025-12-16	2025-12-16	S Sale	2.7 Anzalone Christopher Richard Chief Executive Officer Executive Director	14,095 -0.4% 62.12 US$875,581	14,095 -0.4%	62.12	US$875,581

Explore more

More insider trading research around Arrowhead Pharmaceuticals Inc

More insider trades in United States

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Biotechnology & Medical Research companies with insider activity

Insider trading in North America

Arrowhead Pharmaceuticals Inc (ARWR)

Track

Featured in screeners

Stock chart

Transactions

Insider

Sort by

Trades

Explore more